Tandem Diabetes Care (TNDM)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$17.43+1.63%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tandem Diabetes Care’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-9.8%

+10% or more+5%0%−5%−10% or less

0.14 → 0.13 EPS · FY ending Dec 31, 2027 · 17 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 17; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	304.35M
EPS	—	0.175
FY 2026 · Annual
International revenue	$335M–$340M	—
Revenue	—	1.07B
United States revenue	$730M–$745M	—
EPS	—	-0.672
FY 2027 · Annual
Revenue	—	1.21B
EPS	—	0.128

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Positive cash from operations of at least $11 million quarterly	Cash from operations turned positive to $11.1 million in Q1 2026.	Improving	Cash from operations falls below zero for two consecutive quarters	Cash from operations: $-34.63M FY2026-Q2; GAAP. Published target: >= $11 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-34,630,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 4 of last 4 quarters. Cash from operating activities improved from negative $18.3 million in 2025-Q1 to positive $11.1 million in 2026-Q2. Management has emphasized improving cash flow and free cash flow, and the financials show delivering progress. Delivery assessment Oct 24, 2026
Gross margin improves to about 56.5%	Gross margin improved to 55% and is guided to 56.5% for 2026.	Intact	Gross margin falls below 53% in FY26	Gross margin: 56.87% FY2026-Q2; GAAP. Published target: 56.5%. Target period is not explicitly aligned with this observation. Source published Aug 6, 202656.874607 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 607597b8-49d7-45e0-b125-1145eca78c7e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 4 of last 4 quarters. Gross margin improved from 52% in 2025-Q2 to 57% in 2026-Q2, and operating loss margin improved from -22% to -5% over the same period. Management consistently emphasized margin and profitability improvement, and the financials show delivering progress. Delivery assessment Oct 24, 2026
Annual revenue grows to about $1.075 billion	A primary condition in Tandem Diabetes Care's published investment case. The stated target is ~$1.075B.	Intact	Annual revenue falls below $1.0 billion in FY26	Revenue: $254.56M FY2026-Q2; GAAP. Published target: ~$1.075B. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026254,560,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 607597b8-49d7-45e0-b125-1145eca78c7e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $234.4 million in 2025-Q1 to $254.6 million in 2026-Q2 (+6%), with pump shipments increasing to over 33,000 pumps worldwide in 2026-Q2. Management consistently emphasized growth through expanded sales, pump shipments, and pay-as-you-go adoption, and the financials show delivering progress. Delivery assessment Oct 24, 2026
Pump shipments grow about 10-11% annually	The company is expanding internationally and increasing pump shipments as planned.	Broken	Shipment growth falls below 5% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $234.4 million in 2025-Q1 to $254.6 million in 2026-Q2 (+6%), with pump shipments increasing to over 33,000 pumps worldwide in 2026-Q2. Management consistently emphasized growth through expanded sales, pump shipments, and pay-as-you-go adoption, and the financials show delivering progress. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.13

$0.11 → $0.13 · observed estimates

FY2027 revenue$1.21B

$1.21B → $1.21B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.11	$1,206,554,110	18 / 22
2026-07-25	$0.11	$1,206,554,110	18 / 22
2026-07-26	$0.11	$1,206,554,110	18 / 22
2026-07-27	$0.11	$1,206,554,110	18 / 22
2026-07-28	$0.11	$1,206,554,110	18 / 22
2026-07-29	$0.13	$1,206,778,258	14 / 17
2026-07-30	$0.11	$1,205,859,400	19 / 23
2026-07-31	$0.13	$1,206,006,711	15 / 17
2026-08-01	$0.13	$1,206,006,711	15 / 17
2026-08-02	$0.11	$1,205,859,400	19 / 23
2026-08-03	$0.13	$1,206,006,711	15 / 17
2026-08-04	$0.11	$1,205,859,400	19 / 23
2026-08-05	$0.11	$1,208,144,050	19 / 23
2026-08-06	$0.13	$1,206,006,711	15 / 17
2026-08-08	$0.12	$1,205,844,570	13 / 23
2026-08-09	$0.12	$1,205,844,570	13 / 23
2026-08-10	$0.13	$1,206,006,711	15 / 17
2026-08-12	$0.18	$1,205,019,620	19 / 23
2026-08-13	$0.13	$1,206,006,711	15 / 17
2026-08-14	$0.13	$1,206,006,711	15 / 17
2026-08-15	$0.13	$1,206,006,711	15 / 17
2026-08-16	$0.13	$1,206,006,711	15 / 17
2026-08-17	$0.13	$1,206,006,711	15 / 17
2026-08-18	$0.13	$1,206,006,711	15 / 17
2026-08-19	$0.13	$1,206,006,711	15 / 17
2026-08-20	$0.14	$1,205,330,573	15 / 17
2026-08-21	$0.14	$1,205,330,573	15 / 17
2026-08-22	$0.14	$1,205,674,952	15 / 17
2026-08-23	$0.14	$1,205,674,952	16 / 18
2026-08-24	$0.14	$1,205,674,952	16 / 18
2026-08-25	$0.14	$1,205,674,952	16 / 18
2026-08-26	$0.14	$1,205,674,952	16 / 18
2026-08-27	$0.14	$1,205,674,952	16 / 18
2026-08-28	$0.14	$1,205,674,952	16 / 18
2026-08-29	$0.14	$1,205,674,952	16 / 18
2026-08-30	$0.14	$1,205,674,952	16 / 18
2026-08-31	$0.14	$1,205,674,952	16 / 18
2026-09-01	$0.14	$1,205,674,952	16 / 18
2026-09-02	$0.14	$1,205,674,952	16 / 18
2026-09-03	$0.14	$1,205,674,952	16 / 18
2026-09-04	$0.14	$1,205,674,952	16 / 18
2026-09-05	$0.14	$1,205,674,952	16 / 18
2026-09-06	$0.14	$1,205,674,952	16 / 18
2026-09-07	$0.14	$1,205,674,952	16 / 18
2026-09-08	$0.14	$1,205,674,952	16 / 18
2026-09-09	$0.14	$1,205,674,952	16 / 18
2026-09-10	$0.14	$1,205,674,952	16 / 18
2026-09-11	$0.14	$1,205,674,952	16 / 18
2026-09-12	$0.14	$1,205,674,952	16 / 18
2026-09-13	$0.14	$1,205,674,952	16 / 18
2026-09-14	$0.14	$1,205,674,952	16 / 18
2026-09-15	$0.14	$1,205,674,952	16 / 18
2026-09-16	$0.14	$1,205,674,952	16 / 18
2026-09-17	$0.14	$1,205,674,952	16 / 18
2026-09-18	$0.14	$1,205,674,952	16 / 18
2026-09-19	$0.14	$1,205,674,952	16 / 18
2026-09-20	$0.14	$1,205,674,952	16 / 18
2026-09-21	$0.14	$1,205,674,952	16 / 18
2026-09-22	$0.14	$1,205,674,952	16 / 18
2026-09-23	$0.14	$1,205,674,952	16 / 18
2026-09-24	$0.14	$1,205,674,952	16 / 18
2026-09-25	$0.14	$1,205,444,517	16 / 18
2026-09-26	$0.14	$1,205,444,517	16 / 18
2026-09-27	$0.14	$1,205,444,517	16 / 18
2026-09-28	$0.14	$1,205,444,517	16 / 18
2026-09-29	$0.14	$1,205,444,517	16 / 18
2026-09-30	$0.14	$1,205,444,517	16 / 18
2026-10-01	$0.14	$1,205,170,604	16 / 18
2026-10-02	$0.14	$1,205,144,517	16 / 18
2026-10-03	$0.14	$1,205,144,517	16 / 18
2026-10-04	$0.14	$1,205,144,517	16 / 18
2026-10-05	$0.14	$1,205,144,517	16 / 18
2026-10-06	$0.14	$1,205,144,517	16 / 18
2026-10-07	$0.14	$1,205,144,517	16 / 18
2026-10-08	$0.13	$1,205,144,517	16 / 18
2026-10-09	$0.13	$1,205,144,517	17 / 18
2026-10-10	$0.13	$1,205,144,517	17 / 18
2026-10-11	$0.13	$1,205,144,517	17 / 18
2026-10-12	$0.13	$1,205,144,517	17 / 18
2026-10-13	$0.13	$1,205,144,517	17 / 18
2026-10-14	$0.13	$1,205,144,517	17 / 18
2026-10-15	$0.13	$1,205,137,270	17 / 18
2026-10-16	$0.13	$1,205,137,270	17 / 18
2026-10-17	$0.13	$1,205,137,270	17 / 18
2026-10-18	$0.13	$1,205,137,270	17 / 18
2026-10-19	$0.13	$1,205,137,270	17 / 18
2026-10-20	$0.13	$1,205,137,270	17 / 18
2026-10-21	$0.13	$1,205,137,270	17 / 18
2026-10-22	$0.13	$1,205,137,270	17 / 18
2026-10-23	$0.13	$1,205,137,270	17 / 18
2026-10-24	$0.13	$1,205,137,270	17 / 18

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	13	12
2026-06-01	13	11
2026-07-01	13	11
2026-08-01	13	11
2026-09-01	14	11
2026-10-01	14	12

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 12 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Mizuho SecuritiesOct 13 · prior May 8

$24.00 → $18.00-25.0%

BarclaysOct 6 · prior May 11

$55.00 → $18.00-67.3%

$0$30.25$60.50

0 raises · 2 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Positive cash from operations of at least $11 million quarterlyCash from operations: $-34.63M
Gross margin improves to about 56.5%Gross margin: 56.87%
Annual revenue grows to about $1.075 billionRevenue: $254.56M
Pump shipments grow about 10-11% annuallyPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-54.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tandem Diabetes Care outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented medical-device business, not yet a proven profitable compounder. Its long-term thesis is intact, with recent execution supporting growth and better margins, but profitability remains unproven.

What's priced into Tandem Diabetes Care

The evidence describes TNDM as cheap versus peers, while also showing that its valuation carries a 41% premium versus peers. The model has low confidence, and the negative expectations gap suggests market assumptions may be difficult to meet; no evidence specifies exactly what growth or profit level is already assumed.

What the fundamentals likely do

Near-term results show progress: revenue rose from $234.4 million in 2025-Q1 to $254.6 million in 2026-Q2, while pump shipments exceeded 33,000 in 2026-Q2. Gross margin improved and the operating loss margin narrowed, but the company remains loss-making; guidance was reaffirmed on 2026-08-06, and a future cut would be a meaningful risk.

What Tandem Diabetes Care hinges on

Over the next few quarters, the thesis depends on continued revenue and pump-shipment growth, further margin improvement, and stronger cash generation. A guidance cut or worsening employment data could weigh on the business outlook, while continued strong results and guidance from healthcare peers could support the sector backdrop.